AI Insight
This study analyzed DNA methylation patterns and UHRF1 expression across three cancer types (gastric, kidney, and adrenal) to understand why UHRF1 predicts opposite outcomes in different cancers. Researchers identified a four-class classification system linking UHRF1 levels and embryonic developmental gene activity that explains this paradox: high UHRF1 predicts better survival in gastric cancer but worse survival in kidney and adrenal cancers. The prognostic pattern depends on whether UHRF1-driven methylation silences developmental genes (favorable in gastric cancer) or activates them through alternative mechanisms while creating immunosuppressive environments (unfavorable in kidney and adrenal cancers).
Why it matters
This classification system outperformed existing prognostic tools and remained predictive even after accounting for cancer stage, potentially improving patient risk stratification and treatment decisions. The findings suggest that understanding tissue-specific epigenetic patterns could help explain why biomarkers behave differently across cancer types and may guide development of epigenetic therapies tailored to specific tumor lineages.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Aberrant DNA methylation is a hallmark of cancer, but its clinical interpretation remains debated. UHRF1, a key epigenetic adaptor for DNA methylation maintenance and chromatin bivalency regulation in embryonic stem cells, is frequently overexpressed yet shows context-dependent prognostic behaviour. By integrating bulk and single-cell transcriptomics, CpG-resolution methylation, developmental chromatin states, immune profiling and clinical outcomes across gastric (STAD), clear-cell renal (KIRC) and adrenal (ACC) carcinomas, we identified a four-class UHRF1-embryonic morphogenesis (UHRF1-EM) framework resolving this paradox. This axis revealed an inverse prognostic pattern: whilst across all three tumours EM-low and EM-high states mark better or worse prognosis, respectively, UHRF1-high levels associate with favourable outcome in STAD (UH-EML), and unfavourable in KIRC and ACC (UH-EMH). The classification proved reproducible and independently prognostic after adjustment for stage and molecular subtypes, outperforming existing classifiers and exceeding pathological stage in KIRC and ACC. Multivariable models incorporating UHRF1-EM yielded uniformly positive {Delta}C-indices.
Hypermethylation associated with the UHRF1-EM axis was enriched at ESC bivalent developmental loci (EM and oncofoetal genes), but not at housekeeping cell-cycle sites. In STAD, this pattern was related to oncofoetal gene downregulation and best prognosis, whereas in KIRC and ACC it matched with gene-body/enhancer methylation, higher EM expression, immunosuppressive microenvironments and worst prognosis.
Together, these findings establish the UHRF1-EM axis as a clinically robust molecular classifier and support a mechanistic model in which tumour-specific epigenetic engagement of developmental loci may contribute to the prognostic inversion, providing a foundation for further mechanistic experimental validation.